Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CERVAVAC
- Development stage
- Phase 4
- Lead developer
- Serum Institute of India
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CERVAVAC is India's first indigenous quadrivalent human papillomavirus (HPV) vaccine, developed by the Serum Institute of India (SII) in partnership with the Department of Biotechnology (DBT), the Biotechnology Industry Research Assistance Council (BIRAC), and the Bill and Melinda Gates Foundation. The vaccine is composed of recombinant virus-like particles (VLPs) based on the L1 protein of HPV types 6, 11, 16, and 18. It is indicated for the prevention of cervical, vulvar, vaginal, and anal cancers, as well as genital warts and associated precancerous or dysplastic lesions in both females and males aged 9 through 26. CERVAVAC is designed to provide a cost-effective alternative to existing HPV vaccines, facilitating broader access to cervical cancer prevention programs.
- Brand names
- CERVAVAC
- Other names
- quadrivalent human papillomavirus vaccineSII HPV vaccine
02
Targets
HPV16 (Human papillomavirus type 16)HPV18 L1HPV11 L1HPV6 L1 (Human papillomavirus type 6 major capsid protein L1)
Beyond the preview
Go deeper on CERVAVAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CERVAVAC.